NanoViricides, Inc. (NYSE American: NNVC) has begun enrolling and dosing patients in a Phase II clinical trial of NV-387 Oral Gummies for the treatment of Bundibugyo Ebolavirus and other Ebola viruses. The trial is taking place at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC). According to the company, the Phase IIA portion started enrollment and dosing around September 23 and is designed to establish a safe and well-tolerated dosing protocol. That protocol will then be used in the Phase IIB portion, which will evaluate the drug's safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077.
This development matters because Ebola remains a highly lethal viral disease with limited treatment options, particularly in outbreak-prone regions like the DRC. An oral formulation could simplify administration in resource-limited settings, where injectable therapies may be challenging to deploy. If successful, NV-387 could become an important tool in outbreak response and potentially pave the way for broader antiviral applications. The company notes that NV-387 is a broad-spectrum antiviral drug candidate being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. This trial represents a significant milestone for NanoViricides as it advances its lead candidate into Phase II human clinical trials.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections, excluding cancer and similar diseases. NanoViricides holds broad, exclusive, sub-licensable field licenses from TheraCour for several licensed fields. Its business model focuses on licensing technology for specific application verticals of specific viruses. For more details, the full press release is available at https://ibn.fm/qC4Hk.
In addition to NV-387, NanoViricides is developing NV-HHV-1 for the treatment of Shingles. The company is also working on drugs against a range of viral diseases including oral and genital Herpes, viral diseases of the eye such as EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. Its platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
As with any drug development, the path is lengthy and requires substantial capital. There can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance that successful lab results will lead to successful clinical trials or a pharmaceutical product. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. Through InvestorWire, it provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
